Pyrophosphate Reagent

<strong>Pyrophosphate Reagent</strong>_x000D_ <strong>Catalog number:</strong> B2012772_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 1 Vial_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Lyophilized Powder_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> Pyrophosphate detection reagent_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Chandrashekar P, Masri A. Incidental extra-cardiac uptake of (99m)Tc-pyrophosphate J Nucl Cardiol. 2022 Oct;29(5):2721-2723._x000D_ 2: Shears SB. Towards pharmacological intervention in inositol pyrophosphate signalling Biochem Soc Trans. 2016 Feb;44(1):191-6._x000D_ 3: Sharain K, Homb A, Chareonthaitawee P, AbouEzzeddine OF. (99m)Technetium-pyrophosphate cardiac scintigraphy cases from a busy nuclear cardiology laboratory J Nucl Cardiol. 2022 Oct;29(5):2157-2167._x000D_ 4: Roshankar G, White GC, Cadet S, Fine NM, Chan D, White JA, Jimenez-Zepeda V, Slomka PJ, Miller RJH. Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis J Nucl Cardiol. 2022 Oct;29(5):2679-2690._x000D_ 5: Pandey S, Siddiqi OK. Tc-99m pyrophosphate imaging for transthyretin cardiac amyloidosis: Importance of estimation of cancer risk with the modality J Nucl Cardiol. 2020 Feb;27(1):225-227._x000D_ 6: Yang H, Liu Z, Liu C, Zhang Y. FeMoO(4) nanospheres-based nanozymatic colorimetry for rapid and sensitive pyrophosphate detection J Mater Chem B. 2022 Jan 5;10(2):321-327._x000D_ 7: Castaño A, Maurer MS, Bokhari S. Technetium 99m pyrophosphate radioisotope for diagnosis and prognosis of transthyretin cardiac amyloidosis: A call for collaboration J Nucl Cardiol. 2018 Aug;25(4):1257-1259._x000D_ 8: Miller EJ, Campisi R, Shah NR, McMahon S, Cuddy S, Gallegos-Kattan C, Maurer MS, Damy T, Slart RHJA, Bhatia K, Einstein AJ. Radiopharmaceutical supply disruptions and the use of (99m)Tc-hydroxymethylene diphosphonate as an alternative to (99m)Tc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: An ASNC Information Statement J Nucl Cardiol. 2022 Oct;29(5):2748-2760._x000D_ 9: Abazid RM, Romsa JG, Warrington JC, Stodilka RZ, Davey RA, De S, Laidley DL, Vezina WC, Akincioglu C. Tc-99m pyrophosphate left atrial uptake in patients with atrial fibrillation and cardiac amyloidosis J Nucl Cardiol. 2022 Oct;29(5):2731-2733._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/29332821">10: Terenteva EA, Apyari VV, Dmitrienko SG, Garshev AV, Volkov PA, Zolotov YA. Determination of pyrophosphate and sulfate using polyhexamethylene guanidine hydrochloride-stabilized silver nanoparticles Talanta. 2018 Apr 1;180:346-351. </a>_x000D_ _x000D_ <strong>Products Related to Pyrophosphate Reagent can be found at</strong> <a href="https://moleculardepot.com/product-category/Chemicals/"> Chemicals</a>